N,n-disubstituted amides that inhibit the binding of integrins to their receptors
CA 2328990 C · Owner: Texas Biotechnology Corporation · Inventors: Raju, Bore G.; Lin, Shuqun; Grabbe, Vanessa O.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for the inhibition of the binding of .alpha.4.beta.1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which .alpha.4.beta.1 is involved.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1999 and granted January 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 15, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.